好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neuropsychological Outcomes in the Aftermath of New-Onset and Super-Refractory Status Epilepticus
Epilepsy/Clinical Neurophysiology (EEG)
P2 - Poster Session 2 (8:00 AM-9:00 AM)
9-002

To describe long-term neuropsychological and clinical outcomes of new-onset refractory status epilepticus (NORSE) and super-refractory status epilepticus (SRSE) survivors.
Long-term neuropsychological sequelae in NORSE/SRSE survivors are under-explored, partly due to the brevity of assessments that are commonly used. This impacts patient care and limits clinicians’ ability to predict outcomes. More robust evidence is needed to better define the neuropsychological profile of NORSE/SRSE survivors, and to further elucidate clinical factors that may be related to neuropsychological outcomes.
This is a multi-site retrospective study, involving one Canadian and three American sites. People with SRSE (with or without NORSE) from 2000 to 2023 with subsequent clinical neuropsychological evaluations were enrolled. Neuropsychological outcomes were organized based on the International Classification of Cognitive Disorders in Epilepsy (IC-CoDE). Accordingly, data was organized for presented analyses into generalized impairment (impairment in at least three domains) and less than generalized impairment. Clinical factors were gathered from medical records.
Among the 20 participants (13 adult, seven pediatric; 10 females), 14 were generally impaired, two bi-domain impaired, and three single-domain impaired, and one participant had intact cognition. No associations were found between IC-CoDE classifications and sex, age at Intensive Care Unit (ICU) admission, adult versus pediatric, age at time of neuropsychological testing, or time since ICU discharge. Regarding specific domains, 18 were impaired in memory, 14 in executive functioning, 13 in language, 12 in attention and processing speed, and six in visuospatial abilities. Post-SE, 17 participants developed epilepsy. The mean time between ICU admission and time of neuropsychological testing was 3.25 years. Data collection is ongoing; the most up-to-data, including a comparison of the neuropsychological assessments implemented across sites, will be presented.

This study details the long-term neuropsychological outcomes of NORSE/SRSE survivors. Sites’ methods of long-term clinical care and assessment, and various patient outcomes may inform recommendations for clinical care.
Authors/Disclosures
Hannah G. Gray, MSc
PRESENTER 		Ms. Gray has received personal compensation in the range of $500-$4,999 for serving as a AAN 2025 Annual Meeting Abstract Co-Author and Presenter with Creyos.
Karnig Kazazian, PhD Dr. Kazazian has nothing to disclose.
Alexandre d. Castro, MD Dr. Castro has nothing to disclose.
Bahar Madani (portland state University) Bahar Madani has nothing to disclose.
Anima Shrestha, MD Miss Shrestha has nothing to disclose.
Krista L. Eschbach, MD (Childrens Hospital Colorado) The institution of Dr. Eschbach has received research support from Neurocrine Biosciences. The institution of Dr. Eschbach has received research support from UCB Biopharma. The institution of Dr. Eschbach has received research support from Pediatric Epilepsy Research Foundation. Dr. Eschbach has a non-compensated relationship as a Medical Science Advisory Board Member with NORSE Institute that is relevant to AAN interests or activities.
Margaret Gopaul, PhD (Yale School of Medicine) Dr. Gopaul has nothing to disclose.
Aurelie Hanin, PhD (Yale University School of Medicine) Dr. Hanin has nothing to disclose.
Lawrence J. Hirsch, MD, FAAN (Yale University Comprehensive Epilepsy Center) Dr. Hirsch has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ceribell. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for marinus. The institution of Dr. Hirsch has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Natus. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Rapport Therapeutics. Dr. Hirsch has received publishing royalties from a publication relating to health care. Dr. Hirsch has received publishing royalties from a publication relating to health care. Dr. Hirsch has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker; Faculty for Fellows' training course with Neuropace. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Natus.
Marissa Kellogg, MD, MPH, FAAN (VA Portland Healthcare System, Dept of Neurology) The institution of Dr. Kellogg has received research support from VA & DoD.
Ana Suller Marti, MD (University Hospital London Ontario) Dr. Suller Marti has nothing to disclose.
Teneille Gofton, MD (London Health Sciences Centre) The institution of Dr. Gofton has received research support from Government of Canada. The institution of Dr. Gofton has received research support from Canadian Institutes of Health Research. The institution of Dr. Gofton has received research support from Academic Medical Organisation of Southwestern Ontario. The institution of Dr. Gofton has received research support from Lawson Health Research Institute. Dr. Gofton has a non-compensated relationship as a Medical Advisory Board Member with NORSE Institute that is relevant to AAN interests or activities.